Tag
A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlig
A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited react
A multicenter randomized noninferiority trial found that GP observation after pediatric ventilation tube insertion produced audiometric outcomes at 2 years that were noninferior to routine ENT follow-up, with no increase in complications.
A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuation
BabyScreen+ shows clinically accredited whole‑genome sequencing from dried blood spots can be integrated into newborn screening at scale: 1.6% of 1,000 babies had high‑chance actionable findings, median return 13 days, strong parental accep
A multicenter test-negative case-control study in France found high and sustained effectiveness of nirsevimab against RSV bronchiolitis in infants across two consecutive seasons (83.2% and 89.3%), despite emergence of RSV-B mutations.
A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12
Compositional analysis of the PedCARE cohort suggests that an early period of relative rest combined with above-average light and moderate-to-vigorous activity over the first two weeks is associated with lower postconcussion symptom burden
The FDA has approved linaclotide (Linzess) for treating irritable bowel syndrome with constipation (IBS-C) in children 7 and older, marking the first official treatment option for pediatric IBS-C.
A prospective pediatric study shows forehead NIRS (INVOS 5100C) underestimates regional oxygenation in children with darker skin, producing clinically meaningful bias and raising concerns about equity in monitoring and device validation.
A prospective cross-sectional study finds unilateral chronic otitis media with effusion (COME) in children is associated with poorer spatial release from masking and high tinnitus prevalence, suggesting potential central auditory consequenc
A retrospective 10‑year series from Perth Children’s Hospital reports heterogeneous long‑term outcomes after pediatric cochlear implantation for single‑sided deafness; earlier implantation (within 1 year) was associated with greater l
A 5.5-year prospective cohort found lower-extremity apophysitis common in schoolchildren (1265 episodes in 1670 children), median symptom duration 3–4 weeks, and higher risk with soccer, handball, basketball and jump gymnastics but not from
This study identifies clinical and demographic factors associated with positive blood cultures in hospitalized children across nine African and Asian countries, aiming to improve diagnostic stewardship amidst resource constraints.
A comprehensive study identifies key clinical and temporal risk factors associated with severe invasive group A streptococcal disease in children, highlighting increased severity and incidence post-COVID-19 pandemic in the Netherlands.
This study links EBV seropositivity to immune dysregulation and increased mortality in pediatric sepsis, highlighting potential pathways for targeted therapies.
This systematic review and meta-analysis evaluates the efficacy and safety of pharmacological therapies for functional constipation in children, identifying polyethylene glycol as the preferred first-line treatment based on moderate-certain
This systematic review and meta-analysis assess the additional protection from a second dose of influenza vaccine in vaccine-naive children under nine years old, highlighting significant benefits particularly for those under three years.
The American Academy of Pediatrics recommends COVID-19 vaccination for all young children aged 6-23 months, diverging from current CDC policies that advise shared decision-making for healthy children. This review analyzes epidemiologic data
A multicenter study in Japan found that adequate daptomycin dosing significantly improves clinical outcomes in pediatric patients, while adverse events can occur regardless of renal function.
